Company intelligence / Profile preview
Oligovax
Belgiumoligovax.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oligovax has developed Litenimod, a synthetic TLR9 agonist designed to stimulate both innate and adaptive immune responses against cancer. The company has completed several clinical trials in oncology and continues pre-clinical research on its use as an adjuvant for vaccines and immunotherapies. Early results suggest promising immune activation and potential synergy with other therapies.
- Therapeutic areas
- Oncology
- Modalities
- Synthetic oligonucleotide (specifically TLR9 agonist)Vaccine (cancer vaccine)Small molecule (as Litenimod is a synthetic small molecule oligonucleotide)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Oligovax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oligovax.